Literature DB >> 32150483

Treatment of Patients With Late-Stage Colorectal Cancer: ASCO Resource-Stratified Guideline.

E Gabriela Chiorean1, Govind Nandakumar2,3, Temidayo Fadelu4, Sarah Temin5, Ashley Efrain Alarcon-Rozas6, Suyapa Bejarano7, Adina-Emilia Croitoru8, Surbhi Grover9, Pritesh V Lohar10, Andrew Odhiambo11, Se Hoon Park12, Erika Ruiz Garcia13, Catherine Teh14, Azmina Rose15, Bassem Zaki16, Mary D Chamberlin16.   

Abstract

PURPOSE: To provide expert guidance to clinicians and policymakers in resource-constrained settings on the management of patients with late-stage colorectal cancer.
METHODS: ASCO convened a multidisciplinary, multinational Expert Panel that reviewed existing guidelines, conducted a modified ADAPTE process, and used a formal consensus process with additional experts for two rounds of formal ratings.
RESULTS: Existing sets of guidelines from four guideline developers were identified and reviewed; adapted recommendations from five guidelines form the evidence base and provided evidence to inform the formal consensus process, which resulted in agreement of ≥ 75% on all recommendations. RECOMMENDATIONS: Common elements of symptom management include addressing clinically acute situations. Diagnosis should involve the primary tumor and, in some cases, endoscopy, and staging should involve digital rectal exam and/or imaging, depending on resources available. Most patients receive treatment with chemotherapy, where chemotherapy is available. If, after a period of chemotherapy, patients become candidates for surgical resection with curative intent of both primary tumor and liver or lung metastatic lesions on the basis of evaluation in multidisciplinary tumor boards, the guidelines recommend patients undergo surgery in centers of expertise if possible. On-treatment surveillance includes a combination of taking medical history, performing physical examinations, blood work, and imaging; specifics, including frequency, depend on resource-based setting.Additional information is available at www.asco.org/resource-stratified-guidelines.

Entities:  

Mesh:

Year:  2020        PMID: 32150483      PMCID: PMC7124947          DOI: 10.1200/JGO.19.00367

Source DB:  PubMed          Journal:  JCO Glob Oncol        ISSN: 2687-8941


  68 in total

1.  Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal.

Authors:  R Adam; E Avisar; A Ariche; S Giachetti; D Azoulay; D Castaing; F Kunstlinger; F Levi; F Bismuth
Journal:  Ann Surg Oncol       Date:  2001-05       Impact factor: 5.344

2.  Connecting frontline providers in Africa with distant experts to improve patients' outcomes through Project ECHO: a successful experience in Cameroon.

Authors:  Joel Fokom Domgue; Ellen Baker; Florence Manjuh; Melissa Lopez; Thomas Welty; Kathleen M Schmeler
Journal:  Int J Gynecol Cancer       Date:  2019-05-21       Impact factor: 3.437

Review 3.  Irinotecan and high-dose fluorouracil/leucovorin for metastatic colorectal cancer.

Authors:  J Y Douillard
Journal:  Oncology (Williston Park)       Date:  2000-12       Impact factor: 2.990

Review 4.  Hepatectomy and resection of concomitant extrahepatic disease for colorectal liver metastases--a systematic review.

Authors:  Terence C Chua; Akshat Saxena; Winston Liauw; Francis Chu; David L Morris
Journal:  Eur J Cancer       Date:  2011-12-05       Impact factor: 9.162

5.  Clinicopathological features and prognosis in resectable synchronous and metachronous colorectal liver metastasis.

Authors:  Ming-Shian Tsai; Yen-Hao Su; Ming-Chih Ho; Jin-Tung Liang; Tzu-Ping Chen; Hong-Shiee Lai; Po-Huang Lee
Journal:  Ann Surg Oncol       Date:  2006-11-14       Impact factor: 5.344

6.  Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.

Authors:  A de Gramont; A Figer; M Seymour; M Homerin; A Hmissi; J Cassidy; C Boni; H Cortes-Funes; A Cervantes; G Freyer; D Papamichael; N Le Bail; C Louvet; D Hendler; F de Braud; C Wilson; F Morvan; A Bonetti
Journal:  J Clin Oncol       Date:  2000-08       Impact factor: 44.544

Review 7.  Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group.

Authors:  Bernard Nordlinger; Eric Van Cutsem; Philippe Rougier; Claus-Henning Köhne; Marc Ychou; Alberto Sobrero; Rene Adam; Dag Arvidsson; Alfredo Carrato; Vassilis Georgoulias; Felice Giuliante; Bengt Glimelius; Markus Golling; Thomas Gruenberger; Josep Tabernero; Harpreet Wasan; Graeme Poston
Journal:  Eur J Cancer       Date:  2007-09-04       Impact factor: 9.162

Review 8.  FOLFIRI-bevacizumab as first-line chemotherapy in 3500 patients with advanced colorectal cancer: a pooled analysis of 29 published trials.

Authors:  Fausto Petrelli; Karen Borgonovo; Mary Cabiddu; Mara Ghilardi; Veronica Lonati; Federica Maspero; Maria Grazia Sauta; Giordano Domenico Beretta; Sandro Barni
Journal:  Clin Colorectal Cancer       Date:  2013-06-10       Impact factor: 4.481

9.  ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.

Authors:  E Van Cutsem; A Cervantes; R Adam; A Sobrero; J H Van Krieken; D Aderka; E Aranda Aguilar; A Bardelli; A Benson; G Bodoky; F Ciardiello; A D'Hoore; E Diaz-Rubio; J-Y Douillard; M Ducreux; A Falcone; A Grothey; T Gruenberger; K Haustermans; V Heinemann; P Hoff; C-H Köhne; R Labianca; P Laurent-Puig; B Ma; T Maughan; K Muro; N Normanno; P Österlund; W J G Oyen; D Papamichael; G Pentheroudakis; P Pfeiffer; T J Price; C Punt; J Ricke; A Roth; R Salazar; W Scheithauer; H J Schmoll; J Tabernero; J Taïeb; S Tejpar; H Wasan; T Yoshino; A Zaanan; D Arnold
Journal:  Ann Oncol       Date:  2016-07-05       Impact factor: 32.976

10.  Comparative Effectiveness of Up To Three Lines of Chemotherapy Treatment Plans for Metastatic Colorectal Cancer.

Authors:  Iakovos Toumazis; Murat Kurt; Artemis Toumazi; Loukia G Karacosta; Changhyun Kwon
Journal:  MDM Policy Pract       Date:  2017-08-30
View more
  20 in total

1.  Circulating and Tumor-Infiltrating Immune Checkpoint-Expressing CD8+ Treg/T Cell Subsets and Their Associations with Disease-Free Survival in Colorectal Cancer Patients.

Authors:  Alhasan Alsalman; Mohammad A Al-Mterin; Khaled Murshed; Ferial Alloush; Samia T Al-Shouli; Salman M Toor; Eyad Elkord
Journal:  Cancers (Basel)       Date:  2022-06-29       Impact factor: 6.575

2.  PNA-Modified Liposomes Improve the Delivery Efficacy of CAPIRI for the Synergistic Treatment of Colorectal Cancer.

Authors:  Wenbin Diao; Ben Yang; Sipeng Sun; Anping Wang; Rongguan Kou; Qianyun Ge; Mengqi Shi; Bo Lian; Tongyi Sun; Jingliang Wu; Jingkun Bai; Meihua Qu; Yubing Wang; Wenjing Yu; Zhiqin Gao
Journal:  Front Pharmacol       Date:  2022-06-15       Impact factor: 5.988

Review 3.  Prognostic Models Incorporating RAS Mutation to Predict Survival in Patients with Colorectal Liver Metastases: A Narrative Review.

Authors:  Geoffrey Yuet Mun Wong; Connie Diakos; Mark P Molloy; Thomas J Hugh
Journal:  Cancers (Basel)       Date:  2022-06-30       Impact factor: 6.575

4.  A combined treatment with melatonin and andrographis promotes autophagy and anticancer activity in colorectal cancer.

Authors:  Yinghui Zhao; Chuanxin Wang; Ajay Goel
Journal:  Carcinogenesis       Date:  2022-04-25       Impact factor: 4.741

Review 5.  Evidence-based recommendations for gastrointestinal cancers during the COVID-19 pandemic by the Brazilian Gastrointestinal Tumours Group.

Authors:  Rachel P Riechelmann; Renata D'Alpino Peixoto; Gustavo Dos Santos Fernandes; Rui F Weschenfelder; Gabriel Prolla; Duílio Rocha Filho; Aline Chaves Andrade; Marcela Crosara; Juliana Florinda M Rego; Rene C Gansl; Felipe Coimbra; Samuel Aguiar; Elisângela Carvalho; Paulo M Hoff; Anelisa K Coutinho
Journal:  Ecancermedicalscience       Date:  2020-05-22

6.  HER2 Expression Is Predictive of Survival in Cetuximab Treated Patients with RAS Wild Type Metastatic Colorectal Cancer.

Authors:  Said A Khelwatty; Soozana Puvanenthiran; Sharadah Essapen; Izhar Bagwan; Alan M Seddon; Helmout Modjtahedi
Journal:  Cancers (Basel)       Date:  2021-02-05       Impact factor: 6.639

7.  Reporting quality of practice guidelines on colorectal cancer: evaluation using the RIGHT reporting checklist.

Authors:  Jing Han; Meng Tao; Xuan Wu; Ding Li; Yanfang Ma; Shaheenah Dawood; Colin W Steele; Ker-Kan Tan; Qiming Wang
Journal:  Ann Transl Med       Date:  2021-07

8.  Inoperable de novo metastatic colorectal cancer with primary tumour in situ: Evaluating discordant responses to upfront systemic therapy of the primary tumours and metastatic sites and complications arising from primary tumours (experiences from an Irish Cancer Centre).

Authors:  Ruba A Hamed; Sam Marks; Helen Mcelligott; Roshni Kalachand; Hawa Ibrahim; Said Atyani; Greg Korpanty; Nemer Osman
Journal:  Mol Clin Oncol       Date:  2021-12-21

Review 9.  The Role of p53 Dysfunction in Colorectal Cancer and Its Implication for Therapy.

Authors:  Maurice Michel; Leonard Kaps; Annett Maderer; Peter R Galle; Markus Moehler
Journal:  Cancers (Basel)       Date:  2021-05-11       Impact factor: 6.639

10.  A phase II study of FOLFOXIRI plus bevacizumab as initial chemotherapy for patients with untreated metastatic colorectal cancer: TRICC1414 (BeTRI).

Authors:  Katsunori Shinozaki; Takeshi Yamada; Junichiro Nasu; Toshihiko Matsumoto; Yasuhiro Yuasa; Takeshi Shiraishi; Hiroaki Nagano; Ichiro Moriyama; Toshiyoshi Fujiwara; Masashi Miguchi; Ryosuke Yoshida; Kimiyasu Nozaka; Hiroaki Tanioka; Takeshi Nagasaka; Yasuro Kurisu; Michiya Kobayashi; Kenji Tsuchihashi; Michio Inukai; Takashi Kikuchi; Tomohiro Nishina
Journal:  Int J Clin Oncol       Date:  2020-10-23       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.